benzoxazoles has been researched along with Hypertriglyceridemia in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 10 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Fujikawa, T; Sogabe, Y | 1 |
| Bogdanski, P; Ceska, R; Ginsberg, HN; Hounslow, NJ; Hovingh, GK; Kalina, A; Libis, RA; Senko, Y; Suganami, H; Supryadkina, TV | 1 |
| Endo, H; Kagaya, Y; Kanazawa, M; Kondo, M; Miura, M; Nakamura, A; Saito, H; Sato, K | 1 |
| Dan, K; Fushimi, Y; Isobe, H; Iwamoto, Y; Kaku, K; Kaneto, H; Katakura, Y; Kimura, T; Kusano, T; Mune, T; Nakanishi, S; Obata, A; Ohnishi, M; Sanada, J; Shimoda, M; Tatsumi, F; Wamata, R | 1 |
| Chihara, A; Nakamura, T; Node, K; Sato, E; Tanaka, A | 1 |
| Iitake, C; Koseki, M; Masuda, D; Yamashita, S | 1 |
| Komiya, I; Sunakawa, S; Wakugami, T; Yamamoto, A | 1 |
| Hachisu, Y; Hatanaka, T; Hazama, Y; Kakizaki, S; Kashiwabara, K; Naganuma, A; Nakano, S; Nakano, Y; Saito, N; Tanaka, Y; Tojima, H; Uraoka, T; Yoshida, S; Yoshinaga, T | 1 |
| Arai, H; Araki, E; Ishibashi, S; Matsushita, M; Nojima, T; Suganami, H; Yamashita, S; Yokote, K | 1 |
| Hoshino, T; Ishizuka, K; Kitagawa, K; Seki, M; Toi, S | 1 |
| Arai, H; Araki, E; Ishibashi, S; Suganami, H; Yamashita, S; Yokote, K | 2 |
| Fujioka, Y | 1 |
| Arai, H; Araki, E; Inoguchi, T; Ishibashi, S; Maegawa, H; Nakamura, J; Satoh, J; Suganami, H; Tanizawa, Y; Watada, H; Yamashita, S; Yokote, K; Yoshioka, N | 1 |
5 trial(s) available for benzoxazoles and Hypertriglyceridemia
| Article | Year |
|---|---|
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Topics: Adult; Benzoxazoles; Butyrates; Double-Blind Method; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; PPAR alpha; Triglycerides | 2022 |
Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.
Topics: Adult; Aged; Apolipoprotein A-I; Benzoxazoles; Bezafibrate; Butyrates; Cholesterol, HDL; Cross-Over Studies; Female; Humans; Hypertriglyceridemia; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Treatment Outcome; Triglycerides | 2023 |
Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
Topics: Adult; Aged; Benzoxazoles; Biomarkers; Butyrates; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Japan; Male; Middle Aged; PPAR alpha; Quinolines; Signal Transduction; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2017 |
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Topics: Benzoxazoles; Biomarkers; Butyrates; Cholesterol, HDL; Double-Blind Method; Female; Fenofibrate; Follow-Up Studies; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Prognosis; Triglycerides | 2018 |
Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
Topics: Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Triglycerides | 2019 |
9 other study(ies) available for benzoxazoles and Hypertriglyceridemia
| Article | Year |
|---|---|
Lipid Metabolic Disorder with Varied Clinical Manifestations.
Topics: Adult; Benzoxazoles; Blood Glucose; Butyrates; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Lipid Metabolism Disorders; Male; Retinal Diseases; Xanthomatosis | 2022 |
Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Topics: Benzoxazoles; Humans; Hypertriglyceridemia; PPAR alpha; Retrospective Studies; Triglycerides | 2023 |
Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
Topics: Adult; Atherosclerosis; Benzoxazoles; Butyrates; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Hypertriglyceridemia; Male; Middle Aged; PPAR alpha; Proteins; Proteinuria; Renal Insufficiency; Treatment Outcome | 2020 |
Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
Topics: Adult; Benzoxazoles; Biomarkers; Butyrates; Down-Regulation; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Japan; Male; Middle Aged; PPAR alpha; Preliminary Data; Severity of Illness Index; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2020 |
Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
Topics: Aged; Benzoxazoles; Butyrates; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Humans; Hypertriglyceridemia; Lipids; Male; Middle Aged; Triglycerides | 2021 |
Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study.
Topics: Aged; Benzoxazoles; Butyrates; Humans; Hypertriglyceridemia; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies | 2021 |
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
Topics: Adult; Aged; Benzoxazoles; Biomarkers; Blood Glucose; Butyrates; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Fibroblast Growth Factors; Heart Disease Risk Factors; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Japan; Liver; Liver Function Tests; Male; Middle Aged; PPAR alpha; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Assessment; Time Factors; Treatment Outcome; Triglycerides | 2021 |
Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes.
Topics: Atherosclerosis; Benzoxazoles; Butyrates; Cerebral Arterial Diseases; Humans; Hyperlipidemias; Hypertriglyceridemia; Male; Middle Aged; Prospective Studies; Stroke; Triglycerides | 2022 |
Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia.
Topics: Animals; Benzoxazoles; Butyrates; Hyperlipidemias; Hypertriglyceridemia; Mice; PPAR alpha | 2018 |